How Accurate Is the Fecal Immunochemical Test (FIT)?

The fecal immunochemical test detects about 79% of colorectal cancers at a specificity around 94%, according to a large systematic review and meta-analysis, giving it an overall diagnostic accuracy of roughly 95% for cancer itself. Those numbers sound reassuring, but they conceal important nuances: the test performs very differently depending on the stage and location of a tumor, the hemoglobin cutoff your screening program uses, and whether you are looking for cancer or the precancerous growths that colonoscopy is designed to catch. Understanding those nuances matters, because FIT is the most widely used non-invasive colorectal cancer screening tool in the world.

Overall Sensitivity and Specificity for Cancer

The most frequently cited accuracy figures come from a meta-analysis of studies in average-risk screening populations, which found pooled sensitivity of 79% and specificity of 94% for colorectal cancer detection.¹ That means roughly four out of five people with cancer will get a positive result, and about 94 out of 100 people without cancer will correctly get a negative one. A separate meta-analysis focusing on people already at increased risk for colorectal cancer found even higher sensitivity for cancer, around 93%, though the evidence quality was graded as very low because of wide confidence intervals.² These pooled numbers are averages across many different FIT brands and hemoglobin cutoffs, which is part of why accuracy estimates vary from study to study.

Why Cancer Stage Changes Everything

FIT works by detecting tiny amounts of human hemoglobin in stool, which gets there when a tumor or polyp bleeds into the bowel. Larger, more advanced tumors tend to bleed more, and that biological reality shows up clearly in the data. A study in the Netherlands found that FIT detected early-stage (T1) tumors only about half the time, while it caught more advanced T3 tumors over 90% of the time.³ Broken down by clinical staging, stage I cancers were detected with about 68% sensitivity, while stage II cancers were detected at 92%.³ This is the central tension of FIT-based screening: the test is better at finding cancers that are already further along, which is exactly when you want the earliest possible detection.

The Blind Spot for Precancerous Growths

Colorectal cancer screening ideally catches not just cancer but the advanced adenomas and polyps that precede it. Here, FIT’s accuracy drops substantially. The same increased-risk meta-analysis found FIT sensitivity for advanced neoplasia (a category that includes large polyps and advanced adenomas) at only about 48%.² A dedicated meta-analysis of FIT for advanced adenomas specifically found pooled sensitivity of just 36%.⁴ In other words, FIT misses roughly two-thirds of advanced adenomas. This is not a design flaw so much as a biological limitation: precancerous polyps are smaller and bleed less consistently than established tumors.

The shape of a polyp also matters. One screening study of 60-year-olds found that FIT was better at flagging polyps with a stalk (pedunculated shape) and high-risk features, while flat or broad-based adenomas were more likely to be missed.⁵ Flat lesions tend to erode the bowel surface less, producing less bleeding and less hemoglobin in the stool.

The Cutoff Dial

Unlike the old guaiac-based stool test, quantitative FIT gives a number representing how much hemoglobin is in your sample. A screening program then has to decide where to draw the line between “positive” and “negative.” That cutoff has an enormous impact on accuracy. In a large study called the BLITZ trial, the positivity rate dropped from about 18% at a very low cutoff to under 3% at a high cutoff, and sensitivity fell in step.⁶ A Taiwanese screening study found that raising the cutoff from 50 to 200 ng/mL reduced the positivity rate from about 17% to 10%, while sensitivity for early-stage cancers dropped from roughly 84% to 79%.⁷

This trade-off is not just academic. Countries with limited colonoscopy capacity sometimes raise the cutoff to avoid overwhelming endoscopy services, knowingly accepting that some cancers will be missed. A Dutch study found that bumping the cutoff from 10 to 15 micrograms of hemoglobin per gram of feces reduced colonoscopies by 11% but caused about 6% of advanced neoplasia to be missed.⁸ Modeling work has suggested that lowering the cutoff while extending the screening interval and narrowing the age range could actually save more lives and reduce costs at the same time, by concentrating resources on higher-risk groups.⁹

FIT Compared to the Older Guaiac Test

FIT replaced the guaiac-based fecal occult blood test (gFOBT) as the preferred stool screening method in most countries. The improvement is real but worth quantifying. A head-to-head comparison of several test brands found that the best-performing FIT (InSure) detected advanced colorectal neoplasia with about 26% sensitivity, compared to roughly 7% for the high-sensitivity guaiac test (Hemoccult II SENSA), while specificities remained high for both.¹⁰ A meta-analysis also found that FIT had lower false-positive and false-negative rates than gFOBT.¹¹ FIT also has practical advantages: it does not require dietary restrictions (the guaiac test could react to red meat and certain vegetables), and it needs only one stool sample rather than the three samples guaiac programs typically requested.

How FIT Stacks Up Against Colonoscopy

Colonoscopy is the most thorough single-exam option for colorectal cancer screening, so it sets the benchmark. A landmark randomized trial in Spain found that colonoscopy and FIT detected the same rate of actual cancer at the first screening round, with colorectal cancer found in about 0.1% of participants in each group.¹² But colonoscopy caught far more adenomas: advanced adenomas in about 1.9% of participants versus 0.9% for FIT, and non-advanced adenomas at a tenfold higher rate.¹² A systematic review similarly concluded that FIT’s cancer detection rate was comparable to colonoscopy in average-risk people, but its detection of adenomas was meaningfully lower.¹³

The practical argument for FIT has always been that more people will actually do it. A test that sits on a shelf helps no one, and colonoscopy uptake rates tend to be lower because of the bowel preparation, sedation, and time commitment involved. FIT-based programs partially compensate for per-test lower sensitivity by repeating the test every one to two years, catching what a single round misses.

Repeated Testing Compensates for Single-Round Misses

The value of FIT really emerges over multiple screening rounds. A study following people in a colonoscopy surveillance program found that the risk of advanced neoplasia dropped progressively with each consecutive negative FIT. After one negative test, the incidence of advanced neoplasia was about 11%, but after four consecutive negative tests it had fallen to about 6%.¹⁴ Each additional negative round roughly halved the remaining risk compared to just one negative test. This is the logic behind biennial FIT programs: the test is imperfect on any given day, but repeated sampling catches intermittent bleeding that a single test might miss.

Interval Cancers After a Negative FIT

No screening test catches everything, and cancers that appear between screening rounds after a negative result are called interval cancers. In the New Zealand Bowel Screening Pilot, about 21% of all colorectal cancers diagnosed during the program were interval cancers that had been missed by a prior negative FIT.¹⁵ Those interval cancers were more likely to be in the right side of the colon, diagnosed at a later stage, and associated with poorer survival. In about 70% of these missed cases, no hemoglobin was detectable at all in the prior sample, suggesting those tumors simply were not bleeding at the time of testing.¹⁵

The cutoff threshold also influences interval cancer rates. A Catalonian study of nearly half a million participants with negative FIT results found that the age-adjusted two-year interval cancer rate was about 9.5 per 10,000 people at a lower cutoff versus about 13.8 per 10,000 at a higher cutoff.¹⁶ Lower cutoffs catch more, but at the cost of more colonoscopies for people who turn out to be fine.

Where the Tumor Sits Matters

Cancers in the left side of the colon and rectum tend to produce higher hemoglobin readings on FIT than right-sided cancers. A community-based cohort study found that the median stool hemoglobin in people who later developed left-sided cancers was about five times higher than for right-sided cancers.¹⁷ This makes sense: stool travels a longer distance from the right colon, giving hemoglobin more time to degrade before reaching the collection point. A symptomatic-patient study showed a similar pattern, with right-sided cancers scattered across a wider range of FIT values, including low ones, highlighting that a low FIT does not reliably rule out right-sided disease.¹⁸

False Positives and What Drives Them

A false-positive FIT means you test positive but no cancer or significant polyp is found on the follow-up colonoscopy. Hemorrhoids are the most well-documented culprit. A Korean study found that people with hemorrhoids had about 2.8 times the odds of a false-positive result compared to those without, and even when hemorrhoids were the only abnormality, the false-positive rate was about 15% versus 3% in people with no such condition.¹⁹ Anal fissures and other non-cancerous sources of lower GI bleeding can do the same.

Medications matter too, though perhaps less than you would expect. A Spanish study found that proton pump inhibitors (commonly prescribed for acid reflux) were associated with roughly 1.8 times the odds of a false-positive FIT. Interestingly, aspirin and other anti-inflammatory drugs, which many people worry about, did not reach significance as independent predictors in that study.²⁰ Current guidelines generally do not require people to stop taking aspirin before a FIT, because the modest effect on false positives is outweighed by the risk of missing a round of screening.

Sex and Age Differences in Accuracy

FIT does not perform identically in men and women. A multi-test comparison found that sensitivity for advanced neoplasia was consistently lower in women than in men across all nine FIT brands tested, while specificity was consistently higher in women.²¹ The practical takeaway: a negative FIT is less reassuring in men than in women when it comes to ruling out advanced neoplasia. Some researchers have proposed using sex-specific cutoff thresholds to equalize performance, but no major national program has adopted that approach yet.

Age also plays a role. A meta-analysis found slightly higher sensitivity in people aged 50 to 59 (about 85%) than in those aged 60 to 69 (about 73%), though the difference was not statistically significant because of high variability between studies.²² For younger adults being evaluated for early-onset colorectal cancer, a UK study found excellent FIT performance in 40- to 49-year-olds, with sensitivity above 90% and near-perfect negative predictive values.²³ However, in very young adults (under 30), positive predictive value was notably low, meaning most positive results in that group turned out to be false alarms.

FIT for Symptomatic Patients, Not Just Screening

FIT was designed for asymptomatic screening, but it is increasingly being used in primary care to help triage people who show up with symptoms like changed bowel habits, abdominal pain, or unexplained weight loss. A joint British guideline drew on a meta-analysis of over 48,000 symptomatic patients and found that FIT sensitivity for cancer was above 87% at a threshold of 10 micrograms per gram, and above 93% at lower thresholds near the limit of detection.²⁴ A Danish study found that in symptomatic patients, FIT outperformed symptom-based assessment alone, and among those with very high FIT readings (above 200 micrograms per gram), 85% actually had cancer.²⁵ This has led to the growing practice of using a negative FIT to safely defer colonoscopy in lower-risk symptomatic patients, potentially avoiding a large number of unnecessary procedures.

When You Get a Positive Result, Follow-Up Timing Matters

A positive FIT is only as useful as the colonoscopy that follows it. A large study of over 70,000 patients found that delays beyond about 10 months were associated with meaningfully worse outcomes: the odds of any cancer were roughly 1.5 times higher, and the odds of advanced-stage cancer roughly doubled, compared to follow-up within the first month.²⁶ Delays beyond a year were associated with more than triple the odds of advanced-stage disease.²⁶ The relationship was not strictly linear; follow-up within six months showed no significant increase in risk relative to the first month. A systematic review confirmed these findings, noting that colonoscopy beyond nine months was consistently linked to higher cancer incidence and later-stage diagnoses across the largest available studies.²⁷

Practical Pitfalls in Sample Collection and Storage

The accuracy numbers from clinical studies assume the sample was collected and handled correctly, which does not always happen in the real world. A UK cohort study found that the most common reason FIT specimens were rejected by the lab was sampling errors, accounting for about 41% of all rejections. These included too little or too much stool on the collection probe, wrong containers, and labeling mistakes.²⁸

Interestingly, how you scrape the sample matters less than you might think. A study that deliberately violated collection instructions across nine different FIT brands found that inserting the sampling rod only once (instead of the recommended multiple times) or skipping the visual check of the notches did reduce measured hemoglobin levels, but the impact on diagnostic performance was generally small. In a counterintuitive finding, overloading the tube with extra stool actually increased sensitivity for cancer by about ten percentage points, at a small cost to specificity.²⁹

Temperature and time are more serious concerns. Hemoglobin in stool degrades over time, faster at room temperature than when refrigerated.³⁰ Returning the sample to the lab promptly and keeping it cool in the meantime is the single most important thing you can do to avoid a falsely low reading. Newer buffer solutions are being developed that better preserve hemoglobin stability even at higher temperatures, which could improve reliability in warmer climates and during mail-in screening programs.³¹

Multi-Biomarker Tests and Where FIT Is Headed

FIT’s biggest weakness is its inability to catch precancerous polyps reliably. Several research groups are working on combining hemoglobin detection with additional stool biomarkers to close that gap. The commercially available stool DNA test (often sold under the brand name Cologuard in the United States) adds DNA methylation markers and has higher sensitivity for both cancer and advanced adenomas than FIT alone, though at a higher cost and with more false positives.³²

A different line of research is combining FIT with fecal calprotectin, a protein associated with gut inflammation. A point-of-care test combining four biomarkers (hemoglobin, transferrin, calprotectin, and lactoferrin) has been evaluated in symptomatic patients and shows promise for reducing unnecessary colonoscopies while improving risk stratification.³³ A meta-analysis of FIT for polyp detection also found that volatile organic compound analysis in stool, when combined with FIT, raised sensitivity for advanced adenomas from about 36% to roughly 89%.⁴ None of these combination approaches have replaced standard FIT in large population screening programs yet, but they represent where the field is heading: layering additional signals on top of hemoglobin to catch what FIT alone misses.